Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
| Autor: | Calabresi PA; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Arnold DL; Montreal Neurological Institute, McGill University, Montreal, QC, Canada/NeuroRx, Montreal, QC, Canada., Sangurdekar D; Biogen, Cambridge, MA, USA., Singh CM; Biogen, Cambridge, MA, USA., Altincatal A; Biogen, Cambridge, MA, USA., de Moor C; Biogen, Cambridge, MA, USA., Engle B; Biogen, Cambridge, MA, USA., Goyal J; Biogen, Cambridge, MA, USA., Deykin A; Biogen, Cambridge, MA, USA., Szak S; Biogen, Cambridge, MA, USA., Kieseier BC; Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany/Biogen, Cambridge, MA, USA., Rudick RA; Biogen, Cambridge, MA, USA., Plavina T; Biogen, Cambridge, MA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Sep; Vol. 27 (10), pp. 1497-1505. Date of Electronic Publication: 2020 Dec 14. |
| DOI: | 10.1177/1352458520972573 |
| Abstrakt: | Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage. Methods: This was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing-remitting MS (RRMS). sNfL was measured every 3 months for 2 years, then every 6 months for 4 years. Regression models explored how sNfL data predicted 4-year values of brain volume, expanded disability status scale score, and T2 lesions. sNfL levels were assessed in those receiving placebo, peginterferon beta-1a, and those with disease activity. Results: Baseline sNfL was a predictor of 4-year brain atrophy and development of new T2 lesions. Clinical ( p = 0.02) and magnetic resonance imaging (MRI) ( p < 0.01) outcomes improved in those receiving peginterferon beta-1a whose sNfL decreased to <16 pg/mL after 12 months versus those whose sNfL remained ⩾16 pg/mL. Mean sNfL levels decreased in peginterferon beta-1a-treated patients and increased in placebo-treated patients (-9.5% vs. 6.8%; p < 0.01). sNfL was higher and more variable in patients with evidence of active MS. Conclusion: These data support sNfL as a prognostic and disease-monitoring biomarker for RRMS. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|